Home
News
Create
Screeners
Insights
Jeevan Scientific Technology
82.
44
+6.49
(+8.55%)
Market Cap
₹164.23 Cr
PE Ratio
-73.03
Industry
Healthcare
Buy
Sell
Company Performance:
1D
+8.55%
1M
+36.29%
6M
+29.40%
1Y
+98.32%
5Y
+10.58%
View Company Insights
Latest news about Jeevan Scientific Technology
Jeevan Scientific Technology Limited Files SEBI Compliance Certificate for Q4 FY26
4 days ago
Jeevan Scientific Technology Limited filed its compliance certificate under SEBI Regulation 74(5) for the quarter ended March 31, 2026, with BSE Limited on April 14, 2026. The company's registrar CIL Securities Limited confirmed no dematerialization requests were received during the quarter. Company Secretary Krishna Sainadh Kodati submitted the certificate, fulfilling mandatory quarterly reporting requirements for listed companies under SEBI's depositories regulations.
Jeevan Scientific Technology Executive Director Sells 1,00,000 Shares in Off-Market Transaction
Mar 31, 2026
Jeevan Scientific Technology Receives US FDA Remote Regulatory Assessment Report
Jan 22, 2026
Padmaja Private Trust Acquires 7.53% Stake in Jeevan Scientific Technology
Jan 07, 2026
Jeevan Scientific Promoters Acquire 30L Warrants in Preferential Allotment
Jan 07, 2026
More news about Jeevan Scientific Technology
18
Dec 25
Jeevan Scientific Acquires 60% Stake in Naya Pharma for ₹10 Cr
Jeevan Scientific Technology Limited has acquired a 60% stake in Naya Pharma Private Limited for ₹10 crores. The acquisition, funded through a preferential issue, aims to expand Jeevan Scientific's presence in the pharmaceutical sector. Naya Pharma, incorporated in 2020, specializes in manufacturing and trading pharmaceutical ingredients. The transaction is classified as a related party deal due to common shareholders and directors between the two companies.
12
Nov 25
Jeevan Scientific Technology Limited Shareholders Approve Key Resolutions in EGM
Jeevan Scientific Technology Limited (JSTL) held an Extraordinary General Meeting on November 12, 2025, where shareholders approved four significant resolutions. These include adopting a new Memorandum of Association, increasing authorized share capital from Rs. 21 crore to Rs. 25 crore, issuing convertible warrants to promoters and non-promoters, and issuing equity shares to non-promoters. All resolutions passed with over 99% votes in favor, indicating strong shareholder support for potential growth and structural changes within the company.
12
Nov 25
Jeevan Scientific Technology Reports Net Loss in Q2 Amid Revenue Decline
Jeevan Scientific Technology Limited reported a consolidated net loss before tax of ₹369.90 lakhs for the half year ended September 30, compared to a profit of ₹5.07 lakhs in the previous fiscal year. Standalone net loss before tax was ₹268.56 lakhs. Despite losses, cash and cash equivalents increased to ₹77.42 lakhs from ₹20.59 lakhs. Total assets rose to ₹8,380.67 lakhs, while current liabilities significantly increased to ₹7,345.27 lakhs. The company's subsidiary, Nayas Laboratories, contributed positively with a net profit after tax of ₹9.50 lakhs for the quarter.
08
Nov 25
Jeevan Scientific Technology Completes US FDA Remote Evaluation Successfully
Jeevan Scientific Technology Limited successfully completed a Remote Interactive Evaluation (RIE) by the US FDA for its Clinical Pharmacology facility. The evaluation, conducted from October 17 to November 6, 2025, covered BA/BE studies, operations, systems, and procedures, concluding with no critical observations. This outcome demonstrates the company's adherence to regulatory standards and may enhance its credibility in the pharmaceutical research sector.
15
Oct 25
Jeevan Scientific Technology Unveils Rs. 30.74 Crore Capital Raising Plan
Jeevan Scientific Technology Limited (JSTL) has approved a capital raising plan of Rs. 30.74 crore through convertible warrants and equity shares. The plan includes issuing 35,00,000 convertible warrants at Rs. 40 per warrant and 41,85,000 equity shares at Rs. 40 per share. The warrants will be allotted to both promoters and non-promoters, while the equity shares are exclusively for non-promoters. The company also plans to increase its authorized share capital from Rs. 21 crore to Rs. 25 crore. An Extraordinary General Meeting is scheduled for November 12, 2025, to seek shareholder approval. Post-allotment, promoters' holding is expected to be 38.37%, with public holding at 61.63%.
Jeevan Scientific Technology
82.
44
+
6.
49
(+
8.
55
%)
1 Year Returns:
+98.32%
Industry Peers
Syngene International
436.60
(+
0.
44
%)
Indegene
487.40
(-
0.
36
%)
Suven Life Sciences
196.08
(+
0.
08
%)
Vimta Labs
478.25
(+
0.
94
%)
Take Solutions
49.16
(+
1.
99
%)
Jeevan Scientific Technology
82.44
(+
8.
55
%)
Bilcare
61.88
(+
0.
31
%)
Adeshwar Meditex
15.45
(-
100.
00
%)
Vanta Bioscience
18.20
(-
0.
11
%)
Get More Market Insights with
Heatmap
FII/DII
Company Filings
MF Holdings
Bulk/ Block Deals
Stock Rental via SLBM
Signals
MTF Insights
F&O Ban - MWPL
Top Deliveries
Market Valuation
IPO